NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-108965 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Neurodegenerative Disorder Therapeutics Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET

7.1 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Pfizer, Inc.

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Novartis AG

16.3 Sanofi S.A.

16.4 Teva Pharmaceutical Industries Ltd.

16.5 UCB S.A.

16.6 F. Hoffmann- La Roche Ltd.

16.7 H. Lundbeck A/S

16.8 Merk KGaA

16.9 GlaxoSmithKline PLC

16.10 AbbVie Inc.

16.11 Bristol Myers Squibb Company

16.12 Boehringer Ingeiheim International GmbH

16.13 Bayer AG

16.14 Eisai Co.

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Indication
Multiple sclerosis
Parkinson's disease
Alzheimer's disease
Spinal Muscular Atrophy
Huntington disease
other Neurodegenerative disorders

By Drug Class  
Immunomodulators
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others

By Route of Administration
Oral
Injectable
Enteral
Transdermal

Companies

Pfizer, Inc.
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
F. Hoffmann- La Roche Ltd.
H. Lundbeck A/S
Merk KGaA
GlaxoSmithKline PLC
AbbVie Inc.
Bristol Myers Squibb Company
Boehringer Ingeiheim International GmbH
Bayer AG
Eisai Co.

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.